A Cardiovascular and Renal Drugs Advisory Committee to the FDA held a public meeting last week to discuss safety considerations in the development of
Continue Reading FDA Advisory Committee Holds Meeting On Contrast Agents
Gadolinium
NJ Creates Mass Tort Consolidation of Gadolinium-Based Contrast Agent Litigation
By Sean Wajert on
Further procedural developments in the Gadolinium-based contrast agent litigation. The New Jersey Supreme Court recently ordered all litigation in the…
Continue Reading NJ Creates Mass Tort Consolidation of Gadolinium-Based Contrast Agent Litigation